Tabla de Contenidos:

Tabla de Contenidos: “…Programación de comunicaciones en red3.1 Conceptos básicos: comunicación entre aplicaciones; 3.1.1 Computación distribuida; 3.1.2 Comunicación entre aplicaciones; 3.1.2.1 Mensaje; 3.1.2.2 Emisor; 3.1.2.3 Receptor; 3.1.2.4 Paquete; 3.1.2.5 Canal de comunicación; 3.1.2.6 Protocolo de comunicaciones; 3.2 Protocolos de comunicaciones: IP, TCP, UDP; 3.2.1 Pila de protocolos IP; 3.2.1.1 Nivel de red; 3.2.1.2 Nivel de Internet; 3.2.1.3 Nivel de transporte; 3.2.1.4 Nivel de aplicación; 3.2.1.5 Funcionamiento de la pila de protocolos; 3.2.2 Protocolo TCP…”

Tabla de Contenidos: “….- Kidney Function after In Vivo Gene Silencing of Uncoupling Protein-2 in Streptozotocin-induced Diabetic Rats.- Adenosine A2 Receptor-mediated Regulation of Renal Hemodynamics and Glomerular Filtration Rate is Abolished in Diabetes.- Can Mitochondrial Cytochrome Oxidase Mediate Hypoxic Vasodilation via Nitric Oxide Metabolism?.…”

Tabla de Contenidos: “…ChIP-seq peaks for vitamin D receptors…”

Tabla de Contenidos: “…Microbiología de las infecciones odontogénicas -- Conclusiones -- Bibliografía -- Capítulo 5.Bases farmacológicas para el tratamiento de las infecciones maxilofaciales -- Introducción -- Definiciones aplicadas en farmacología y en infección bucal -- Agonismo -- Antagonismo -- Aclaramiento (del inglés depuración, Cl) -- Área bajo la curva (ABC o AUC) -- Biodisponibilidad -- Bioequivalencia -- Caries -- Celulitis -- Medicamento -- Concentración mínima inhibitoria (CIM, en inglés MIC) -- Concentración máxima (Cmáx) -- Concentración mínima efectiva (CME) -- Concentración mínima tóxica (CMT) -- Constante de absorción (Ka) -- Constante de eliminación (Ke) -- Distribución -- Eficacia -- Efectividad -- Fármaco -- Excreción -- Farmacocinética -- Absorción -- Farmacodinamia -- Gingivitis -- Infecciones odontogénicas -- Metabolismo o biotransformación -- Mucositis -- Perimplantitis -- Peridontitis -- Período de latencia -- Pulpitis -- Receptor -- Rango terapéutico -- Semivida de absorción (t1/2a) -- Semivida o vida media (t1/2) -- Tiempo máximo (tmáx) -- Unión a proteínas -- Velocidad de absorción -- Velocidad de eliminación -- Volumen de distribución (Vd) -- Epidemiología -- Tratamiento de las infecciones odontogénicas -- Consideraciones en el tratamiento con antimicrobianos de las infecciones de tipo odontogénico -- Elección del fármaco antimicrobiano -- Factores del huésped -- Elección del fármaco antimicrobiano -- Principales antimicrobianos usados en infecciones maxilofaciales -- Otros antibióticos -- Consideraciones farmacológicas específicas de los antimicrobianos recomendados en las infecciones ma -- β-lactámicos -- Otros Beta-lactámicos -- Profilaxis en Endocarditis Infecciosa (EI) -- Antibióticos en el tratamiento de la enfermedad periodontal -- Antibióticos en el tratamiento de la perimplantitis -- Resistencia antibiótica -- Conclusiones…”

Tabla de Contenidos: “…Pavicic Jr. and Shyamasree Datta -- Regulation of macrophage polarization by RON receptor tyrosine kinase signalling / Amitabha Chaudhuri -- Complement, C1q, and C1q-related molecules regulate macrophage polarization / Suzanne S. …”

Tabla de Contenidos: “…Sci. 2022, 23, 14261, doi:10.3390/ijms232214261 . 63 -- Jean Mazella Deciphering Mechanisms of Action of Sortilin/Neurotensin Receptor-3 in the Proliferation Regulation of Colorectal and Other Cancers Reprinted from: Int. …”

Tabla de Contenidos: “…-- 13.1: Introduction -- 13.2: Absorption Filters -- 13.3: Polarization Filters -- 13.4: Polarization in Nature -- 13.5: UV and IR Photography -- Chapter 14: The Limits of Human Vision -- 14.1: Introduction -- 14.2: Structure of the Eye -- 14.3: Operation of the Visual Receptors -- 14.4: Visual Acuity -- 14.5: Sensitivity -- 14.6: Conclusions -- Chapter 15: How Can Color Be Managed? …”

Tabla de Contenidos: “…. -- Nanodelivery Systems Targeting Epidermal Growth Factor Receptors for Glioma Management -- Reprinted from: Pharmaceutics 2020, 12, 1198, doi:10.3390/pharmaceutics12121198 123 -- Yongwhan Choi, Hyounkoo Han, Sangmin Jeon, Hong Yeol Yoon, Hyuncheol Kim and Ick -- Chan Kwon et al. -- Deep Tumor Penetration of Doxorubicin-Loaded Glycol Chitosan Nanoparticles Using -- High-Intensity Focused Ultrasound -- Reprinted from: Pharmaceutics 2020, 12, 974, doi:10.3390/pharmaceutics12100974 153 -- Ragnhild Haugse, Anika Langer, Elisa Thodesen Murvold, Daniela Elena Costea, Bjørn Tore -- Gjertsen and Odd Helge Gilja et al. -- Low-Intensity Sonoporation-Induced Intracellular Signalling of Pancreatic Cancer Cells, -- Fibroblasts and Endothelial Cells -- Reprinted from: Pharmaceutics 2020, 12, 1058, doi:10.3390/pharmaceutics12111058 169 -- B ́arbara Pinto, Ana C. …”

Tabla de Contenidos: “…. -- Nanodelivery Systems Targeting Epidermal Growth Factor Receptors for Glioma Management -- Reprinted from: Pharmaceutics 2020, 12, 1198, doi:10.3390/pharmaceutics12121198 123 -- Yongwhan Choi, Hyounkoo Han, Sangmin Jeon, Hong Yeol Yoon, Hyuncheol Kim and Ick -- Chan Kwon et al. -- Deep Tumor Penetration of Doxorubicin-Loaded Glycol Chitosan Nanoparticles Using -- High-Intensity Focused Ultrasound -- Reprinted from: Pharmaceutics 2020, 12, 974, doi:10.3390/pharmaceutics12100974 153 -- Ragnhild Haugse, Anika Langer, Elisa Thodesen Murvold, Daniela Elena Costea, Bjørn Tore -- Gjertsen and Odd Helge Gilja et al. -- Low-Intensity Sonoporation-Induced Intracellular Signalling of Pancreatic Cancer Cells, -- Fibroblasts and Endothelial Cells -- Reprinted from: Pharmaceutics 2020, 12, 1058, doi:10.3390/pharmaceutics12111058 169 -- B ́arbara Pinto, Ana C. …”

Tabla de Contenidos: “…Development of Medications for the Treatment of Opiate and Cocaine Addictions: Issues for the Government and Private Sector -- Copyright -- Acknowledgments -- Preface -- Note to the Reader -- Contents -- Executive Summary -- STATE OF THE SCIENTIFIC KNOWLEDGE ON ADDICTION -- NIDA'S MEDICATIONS DEVELOPMENT DIVISION -- EFFECTIVENESS OF TREATMENT -- TREATMENT FINANCING -- TRAINING AND EDUCATION -- FEDERAL REGULATORY ISSUES -- Food and Drug Administration -- Drug Enforcement Administration -- STATE REGULATORY ISSUES -- Interim Actions -- Long-Term Actions -- MARKET OBSTACLES AND CREATING INCENTIVES -- Size of the Market -- Drug Pricing and Intellectual Property Rights -- Societal Stigma -- NEED FOR FEDERAL LEADERSHIP -- CONCLUSIONS -- OPTIONS FOR FURTHER CONSIDERATION -- REFERENCES -- 1 Introduction -- PUBLIC-HEALTH REPERCUSSIONS OF ILLICIT DRUG USE -- Health Consequences: Violence -- Health Consequences: AIDS -- Health Consequences: Tuberculosis -- Health Consequences: Drug-exposed Infants -- ECONOMIC COSTS OF ILLICIT DRUG USE TO SOCIETY -- EXTENT OF ILLICIT DRUG USE -- ROLE OF PHARMACOTHERAPY -- REFERENCES -- 2 Overview of the State of Scientific Knowledge Concerning Drug Addiction -- CONCEPTS OF DRUG ADDICTION -- BIOLOGICAL CORRELATES AND PSYCHOPHARMACOLOGY OF ADDICTION -- Opiate Addiction -- Cocaine Addiction -- MDD AND STRATEGIES FOR THE DISCOVERY OF A COCAINE MEDICATION: DESCRIPTION AND CRITICAL ANALYSIS -- Introduction -- Source of Compounds -- Medication Preclinical Screening -- In Vitro Screen-Receptors and Mechanisms of Action -- In Vivo Screen-Behavioral Tests -- Specific Conclusions and Recommendations for the MDD -- Clinical Trials -- Human Behavioral Models -- CONCLUSIONS AND RECOMMENDATIONS -- REFERENCES -- 3 Assessment of the Medications Development Division -- STRUCTURE AND FUNCTIONS OF THE MEDICATIONS DEVELOPMENT DIVISION…”

Tabla de Contenidos: “….) -- DEFICIENCIA CONGÉNITA DE ENZIMAS DEL METABOLISMO DE LOS GLÚCIDOS -- DEFICIENCIA CONGÉNITA DE ENZIMAS DEL METABOLISMO DE COMPUESTOS NITROGENADOS -- ALTERACIONES DEL METABOLISMO DE LA BILIRRUBINA -- ENFERMEDADES DEL SISTEMA DIGESTIVO ASOCIADAS A ALTERACIONES DEL RECEPTOR (...) -- BIBLIOGRAFÍA -- CAPÍTULO 6 LA VESÍCULA BILIAR Y LAS VÍAS BILIARES -- LA VESÍCULA BILIAR -- EL SISTEMA BILIAR -- METABOLISMO DE LA BILIRRUBINA -- CONJUGACIÓN DE LA BILIRRUBINA -- PAPEL DE LA BILIRRUBINA CON LA REGULACIÓN DEL ESTRÉS OXIDATIVO CELULAR -- CICLO CELULAR ANTIOXIDANTE BILIRRUBINA/BILIVERDINA -- ICTERICIA -- BIBLIOGRAFÍA -- CAPÍTULO 7 ALTERACIONES DEL METABOLISMO DE LA VESÍCULA Y LAS VÍAS BILIARES -- ÍCTEROS OBSTRUCTIVOS -- NEOPLASIA DE LA CABEZA DEL PÁNCREAS -- ENFERMEDADES GENÉTICAS QUE PRODUCEN ALTERACIONES EN EL ALMACENAMIENTO O EL (...) -- BIBLIOGRAFÍA…”

Tabla de Contenidos: “…14.3 - Benefits of naps -- 14.4 - Strategic napping -- 14.4.1 - Nap duration -- 14.4.2 - When the nap occurs during the day -- 14.4.3 - Future sleep debt -- 14.4.4 - Sleep inertia -- 14.5 - Napping recommendations for the workplace and for shiftwork -- 14.6 - Nap facilities -- 14.6.1 - Dedicated nap facilities -- References -- Chapter 15 - Compounds that alter sleep and wakefulness -- 15.1 - Over-the-counter substances -- 15.1.1 - Coffee/caffeinated drinks -- 15.1.1.1 - Chart of caffeinated beverages -- 15.1.2 - Alcohol -- 15.1.3 - Nicotine -- 15.1.4 - Antihistamines -- 15.1.5 - Decongestant cough medications -- 15.2 - Prescription medications meant to alter sleep and sleepiness -- 15.2.1 - Benzodiazepines -- 15.2.2 - Nonbenzodiazipines somnogenics -- 15.2.3 - Suvorexant -- 15.2.4 - Modanfinil/armodafinil -- 15.2.5 - Melatonin/melatonin receptor agonists -- 15.3 - Common prescriptions that can alter sleep regulation -- 15.3.1 - β-Blockers -- 15.3.2 - Antidepressants -- 15.3.3 - Corticosteroids -- References -- Chapter 16 - Creating a fatigue risk management system (FRMS) -- 16.1 - Call for fatigue risk management systems (FRMS) -- 16.2 - Purpose of an FRMS -- 16.3 - Roles and responsibilities -- 16.4 - FRMS implementation -- 16.5 - Training -- 16.6 - Hours of service limits -- 16.7 - FRMS resources -- 16.8 - Assessing an FRMS -- 16.9 - FRMS quality assurance questions -- References -- Chapter 17 - Accident investigation -- 17.1 - Investigating accidents, incidents, and near misses -- 17.2 - Considering human factors in an investigation -- 17.3 - Fatigue as a contributing factor in accidents -- 17.4 - Sample NTSB fatigue-related accident investigation -- 17.5 - BP Texas City CSB investigation -- References -- Index -- Back Cover…”

Tabla de Contenidos: “…Sci. 2021, 22, 1884, doi:10.3390/ijms22041884 125 -- George Anderson, Annalucia Carbone and Gianluigi Mazzoccoli -- Tryptophan Metabolites and Aryl Hydrocarbon Receptor in Severe Acute Respiratory -- Syndrome, Coronavirus-2 (SARS-CoV-2) Pathophysiology -- Reprinted from: Int. …”

Tabla de Contenidos: “…-- 12-II CARACTERÍSTICAS DE LOS LST -- 12-III RECEPTOR PARA ANTÍGENOS DE LOS LINFOCITOS T (TCR) -- 12-IV ¿CÓMO SE DESARROLLA LA INMUNIDAD CELULAR? …”

Tabla de Contenidos: “…5.3 Applications of Site-Specific Recombination -- 5.3.1 Integration into a single specific site -- 5.3.2 Integration into two sites -- 5.3.3 Modification of transgenes -- 5.3.4 Gene locus-directed chromosome modification: deletions, inversions and translocations -- 5.4 Conclusions -- 6 Receptor-Mediated Ovary Transduction of Cargo - ReMOT Control: a Comprehensive Review and Detailed Protocol for Implementation -- 6.1 History of Transgenic Methods in Arthropods -- 6.2 Development of CRISPR-based Technologies -- 6.3 Problems with Traditional Embryonic Microinjection -- 6.4 ReMOT Control Development -- 6.5 Summary of ReMOT Control Successes -- 6.5.1 Mosquitoes -- 6.5.2 Non-mosquito insects -- 6.6 Challenges and Future Directions -- 6.7 Recommendations for Adaptation of ReMOT Control to New Species -- 6.8 Generalized ReMOT Control Protocol -- 6.8.1 Prior to ReMOT Control -- 6.8.2 One day before injections -- 6.8.3 On injection day -- 6.8.4 Screening protocol -- 6.8.5 In vitro protein expression protocol -- 7 Site-Directed DNA Sequence Modification Using CRISPR-Cas9 -- 7.1 The CRISPR/Cas9 Revolution -- 7.1.1 CRISPR/Cas systems in bacterial immunity -- 7.1.2 CRISPR/Cas9 as a genome editing tool -- 7.2 Site-Directed Genomic Modifications in Insects (Version 2.0) -- 7.2.1 Designing sgRNA -- 7.2.2 Delivery of Cas9-gRNA complexes -- 7.2.3 Identifying genomic modifications -- 7.3 Applications of CRISPR/Cas9 in Insects -- 7.3.1 Developing markers for mutants -- 7.3.2 Testing gene function before making a gene drive -- 7.3.3 Functional genomics in evolution -- 7.4 Concluding Remarks -- 8 An Introduction to the Molecular Genetics of Gene Drives and Thoughts on Their Gradual Transition to Field Use -- 8.1 Introduction -- 8.2 Molecular Mechanism of CRISPR Homing-based Drive Systems -- 8.3 Population Modification -- 8.4 Population Suppression…”

Tabla de Contenidos: “…-- 2.3 LOS CONDUCTORES -- 2.3.1 Resistencia eléctrica -- 2.3.2 ¿Cómo se mide la resistencia? -- 2.4 LOS RECEPTORES -- 2.5 LA CORRIENTE ELÉCTRICA -- 2.5.1 ¿Cómo se mide la intensidad? …”
Acceso restringido con credenciales UPSA

Tabla de Contenidos: “…Other Miscellaneous Genes -- Atf1 -- Cited2 and Cited4 -- Creb1 -- Ctbp1 and Ctbp2 -- Dawg -- Mafb -- Mediator Subunits Med12 and Med24 -- Mef2 -- Mrf2-- Myb and Mybl2 -- Myocd, Mkl1, Mkl2 -- Nfatc3 and Nfatc4 -- Nfyb -- Nuclear Receptors Nr2f1, Nr2f2, Nr5a1, Nr5a2 -- Rela (NFkB Subunit) -- Srf -- Immediate-Early Genes Sp1, Sp3, and Sp4 -- Stat3 -- Tcof1 -- Tead2 -- Tsc22d1 -- References -- Author Biographies…”

Tabla de Contenidos: “…Fungi 2021, 7, 1049, doi:10.3390/jof7121049 201 -- Sandra Montella-Manuel, Nuria Pujol-Carrion and Maria Angeles de la Torre-Ruiz -- The Cell Wall Integrity Receptor Mtl1 Contributes to Articulate Autophagic Responses When -- Glucose Availability Is Compromised -- Reprinted from: J. …”

Tabla de Contenidos: “…3.5 Conclusion -- Acknowledgements -- References -- 4 Role of Data Mining in Bioinformatics -- 4.1 Introduction -- 4.2 Data Mining Methods/Techniques -- 4.2.1 Classification -- 4.2.1.1 Statistical Techniques -- 4.2.1.2 Clustering Technique -- 4.2.1.3 Visualization -- 4.2.1.4 Induction Decision Tree Technique -- 4.2.1.5 Neural Network -- 4.2.1.6 Association Rule Technique -- 4.2.1.7 Classification -- 4.3 DNA Data Analysis -- 4.4 RNA Data Analysis -- 4.5 Protein Data Analysis -- 4.6 Biomedical Data Analysis -- 4.7 Conclusion and Future Prospects -- References -- 5 In Silico Protein Design and Virtual Screening -- 5.1 Introduction -- 5.2 Virtual Screening Process -- 5.2.1 Before Virtual Screening -- 5.2.2 General Process of Virtual Screening -- 5.2.2.1 Step 1 (The Establishment of the Receptor Model) -- 5.2.2.2 Step 2 (The Generation of Small-Molecule Libraries) -- 5.2.2.3 Step 3 (Molecular Docking) -- 5.2.2.4 Step 4 (Selection of Lead Protein Compounds) -- 5.3 Machine Learning and Scoring Functions -- 5.4 Conclusion and Future Prospects -- References -- 6 New Bioinformatics Platform-Based Approach for Drug Design -- 6.1 Introduction -- 6.2 Platform-Based Approach and Regulatory Perspective -- 6.3 Bioinformatics Tools and Computer-Aided Drug Design -- 6.4 Target Identification -- 6.5 Target Validation -- 6.6 Lead Identification and Optimization -- 6.7 High-Throughput Methods (HTM) -- 6.8 Conclusion and Future Prospects -- References -- 7 Bioinformatics and Its Application Areas -- 7.1 Introduction -- 7.2 Review of Bioinformatics -- 7.3 Bioinformatics Applications in Different Areas -- 7.3.1 Microbial Genome Application -- 7.3.2 Molecular Medicine -- 7.3.3 Agriculture -- 7.4 Conclusion -- References -- 8 DNA Microarray Analysis: From Affymetrix CEL Files to Comparative Gene Expression -- 8.1 Introduction -- 8.2 Data Processing…”